Our estimate revisions are driven by USD/SEK movements (down almost 7% since our Q3 review) lowering both sales and costs. We expect a decent sales quarter from OssDsign, as the company said that the good trends of September continued into October in its recent conference call. Our focus is the sales acceleration in the years ahead, given the company’s investments (doubling the salesforce in 2026E and further clinical evidence).
LÄS MER
